Biotech Rally Sparked by Alzheimer's Drug Has Staying Power

Controversy surrounding Biogen’s Aduhelm could ignite political firestorm over high drug prices, but investors should look past any D.C. drama.

Biotech Rally Sparked by Alzheimer's Drug Has Staying Power
Controversy surrounding Biogen’s Aduhelm could ignite political firestorm over high drug prices, but investors should look past any D.C. drama.